about
SIBLINGs and SPARC families: their emerging roles in pancreatic cancerAcquisition order of Ras and p53 gene alterations defines distinct adrenocortical tumor phenotypesThiazolidinediones regulate adipose lineage dynamics.Quantitative secretome and glycome of primary human adipocytes during insulin resistance.SPARC overexpression suppresses radiation-induced HSP27 and induces the collapse of mitochondrial Δψ in neuroblastoma cellsA p-Median approach for predicting drug response in tumour cells.SPARC fusion protein induces cellular adhesive signaling.Global O-GlcNAc Levels Modulate Transcription of the Adipocyte Secretome during Chronic Insulin Resistance.How lipidomics provides new insight into drug discovery.Aberrant methylation of SPARC in human hepatocellular carcinoma and its clinical implication.Mesenchymal stem/progenitors and other endometrial cell types from women with polycystic ovary syndrome (PCOS) display inflammatory and oncogenic potential.Berberine hydrochloride: anticancer activity and nanoparticulate delivery system.Antiangiogenic and anticancer molecules in cartilage.Stromal expression of SPARC in pancreatic adenocarcinoma.Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis.Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): part I. Albumin-bound betulinic acid nanoparticles (ABBns).Silencing endothelin-3 expression attenuates the malignant behaviors of human melanoma cells by regulating SPARC levels.Secreted Protein Acidic and Rich in Cysteine (SPARC) Enhances Cell Proliferation, Migration, and Epithelial Mesenchymal Transition, and SPARC Expression is Associated with Tumor Grade in Head and Neck Cancer.Clinical significance of SPARC gene expression in patients with gastric cancer.hsa-miR-29c-3p regulates biological function of colorectal cancer by targeting SPARC.Clinical significance of secreted protein, acidic and cysteine-rich gene expression in patients with stage II/III gastric cancer following curative resection and adjuvant chemotherapy with S-1.
P2860
Q27027759-710ACC8B-3AEF-473E-97FE-766AB16949F2Q27333989-3C3BAD2B-60F1-4455-8086-AD975404E30FQ30404426-FB1FFD9E-3A72-4124-8913-7D433F876576Q33749585-617D9C24-6861-422E-A52F-52EF25FB7C32Q33751169-DC9FCBB7-B597-4FC2-AF36-9E10173369FDQ34463528-4C16CACD-B573-46C3-9DF5-CE5F384D183DQ34562147-A34BB06F-B28F-4236-8C1A-DCE764439E4EQ34999404-6CCB4513-B1B7-44D9-A2A5-EE3ED4CF1C90Q35167171-0473697E-6331-40BF-B89E-0067278160A1Q35929159-04F46FA7-D53B-47EC-9368-EB270195D915Q37149626-ED80EC06-B32C-4831-91CD-A5B15BA826E3Q37935557-F043D6EA-180C-4D34-A3FB-F1EC2FCB7B12Q38007565-B591D9C2-F4E9-4757-8CCA-8BEE7872E895Q38108253-0DF6CCE1-B981-4F99-AB02-7660199ED745Q38199932-6DDCB51A-461D-4C01-96C8-2D338D17305EQ38742313-2C414849-CD4F-48EE-B28E-A405FD62913CQ39117240-B091E3BA-9ACF-4A6F-8974-DAD2E4C72394Q41183233-E91C1418-2791-45E2-8257-6446FDEB7AFBQ43940466-622FB715-9BD9-43A6-8F9C-F842BEACA04EQ47152865-AAB51528-E4F9-48D9-AD6F-02BAD8066D82Q54090244-67036125-DFB9-4B51-974D-C753AF0CCAB7
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Anti-cancer role of SPARC, an inhibitor of adipogenesis
@ast
Anti-cancer role of SPARC, an inhibitor of adipogenesis
@en
type
label
Anti-cancer role of SPARC, an inhibitor of adipogenesis
@ast
Anti-cancer role of SPARC, an inhibitor of adipogenesis
@en
prefLabel
Anti-cancer role of SPARC, an inhibitor of adipogenesis
@ast
Anti-cancer role of SPARC, an inhibitor of adipogenesis
@en
P2860
P1476
Anti-cancer role of SPARC, an inhibitor of adipogenesis
@en
P2093
Dipali Sharma
Ganji Purna Chandra Nagaraju
P2860
P304
P356
10.1016/J.CTRV.2010.12.001
P577
2011-01-14T00:00:00Z